WO2011090283A3 - Ｓｈ３ｒｆ２ 발현 또는 활성 억제제를 함유하는 암의 예방 또는 치료용 조성물 - Google Patents

Ｓｈ３ｒｆ２ 발현 또는 활성 억제제를 함유하는 암의 예방 또는 치료용 조성물 Download PDF

Info

Publication number
WO2011090283A3
WO2011090283A3 PCT/KR2011/000108 KR2011000108W WO2011090283A3 WO 2011090283 A3 WO2011090283 A3 WO 2011090283A3 KR 2011000108 W KR2011000108 W KR 2011000108W WO 2011090283 A3 WO2011090283 A3 WO 2011090283A3
Authority
WO
WIPO (PCT)
Prior art keywords
sh3rf2
expression
activity
cancer
preventing
Prior art date
Application number
PCT/KR2011/000108
Other languages
English (en)
French (fr)
Other versions
WO2011090283A2 (ko
Inventor
박경찬
염영일
김태우
박지용
강윤경
양석진
최병중
이동철
손현암
유향숙
Original Assignee
한국생명공학연구원
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 한국생명공학연구원 filed Critical 한국생명공학연구원
Priority to US13/574,055 priority Critical patent/US8809295B2/en
Publication of WO2011090283A2 publication Critical patent/WO2011090283A2/ko
Publication of WO2011090283A3 publication Critical patent/WO2011090283A3/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

본 발명은 SH3RF2(SH3 domain containing ring finger 2)의 발현 또는 활성 억제제를 함유하는 암 예방 또는 치료용 조성물에 관한 것으로, 더욱 상세하게는 다양한 암 조직에서 발현량이 증가하는 SH3RF2 단백질은 암 관련 유전자인 PAK4와 결합하여 SH3RF2의 RING 도메인의 유비퀴틴화 활성에 의해 PAK4 단백질의 세포사멸 억제기능을 조절함으로써, SH3RF2가 발현억제된 암세포는 세포사멸 유도에 민감하게 반응하여 세포사멸이 촉진되고 생체 내 종양 형성능이 감소하므로, SH3RF2의 발현 또는 활성 억제제는 암의 예방 또는 치료를 위한 조성물로서 유용하게 사용될 수 있다.
PCT/KR2011/000108 2010-01-19 2011-01-07 Ｓｈ３ｒｆ２ 발현 또는 활성 억제제를 함유하는 암의 예방 또는 치료용 조성물 WO2011090283A2 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US13/574,055 US8809295B2 (en) 2010-01-19 2011-01-07 Composition containing inhibitors of the expression or activity of SH3RF2 for preventing or treating cancer

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2010-0004770 2010-01-19
KR1020100004770A KR101135173B1 (ko) 2010-01-19 2010-01-19 Ｓｈ３ｒｆ２ 발현 또는 활성 억제제를 함유하는 암의 예방 또는 치료용 조성물

Publications (2)

Publication Number Publication Date
WO2011090283A2 WO2011090283A2 (ko) 2011-07-28
WO2011090283A3 true WO2011090283A3 (ko) 2011-12-01

Family

ID=44307365

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2011/000108 WO2011090283A2 (ko) 2010-01-19 2011-01-07 Ｓｈ３ｒｆ２ 발현 또는 활성 억제제를 함유하는 암의 예방 또는 치료용 조성물

Country Status (3)

Country Link
US (1) US8809295B2 (ko)
KR (1) KR101135173B1 (ko)
WO (1) WO2011090283A2 (ko)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111194724B (zh) * 2020-01-14 2021-05-04 武汉大学 Sh3rf2在制备治疗非酒精性脂肪肝病和/或II型糖尿病的药物中的功能和应用
CN114561475B (zh) * 2022-01-10 2023-07-25 佛山科学技术学院 一种利用分子标记对鸡进行体重选育的方法及其应用及试剂盒
KR102733600B1 (ko) * 2022-01-17 2024-11-21 포항공과대학교 산학협력단 March6 저해제를 포함하는, 항암용 조성물

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009124090A1 (en) * 2008-03-31 2009-10-08 Genentech, Inc. Compositions and methods for treating and diagnosing asthma

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030166229A1 (en) * 2001-01-30 2003-09-04 Mark Shannon Human POSH-like protein 1
WO2008073919A2 (en) * 2006-12-08 2008-06-19 Asuragen, Inc. Mir-20 regulated genes and pathways as targets for therapeutic intervention

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009124090A1 (en) * 2008-03-31 2009-10-08 Genentech, Inc. Compositions and methods for treating and diagnosing asthma

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
LYNN M. KNOWLES ET AL.: "Genome-wide changes accompanying knockdown of fatty acid synthase in breast cancer.", BMC GENOMICS, vol. 8, 2007, pages 168, XP021027982, DOI: doi:10.1186/1471-2164-8-168 *
MIEKO NISHIU ET AL.: "Distinct pattern of gene expression in pyothorax-associated lymphoma (PAL), a lymphoma developing in long-standing inflammation.", CANCER SCI., vol. 95, 2004, pages 828 - 834 *
SHIH-CHICH CHOU ET AL.: "Identification of genetic networks during mesenchymal stem cell transformation into neurons.", CHINESE JOURNAL OF PHYSIOLOGY, vol. 51, no. 4, 2008, pages 230 - 246 *

Also Published As

Publication number Publication date
WO2011090283A2 (ko) 2011-07-28
US20120321635A1 (en) 2012-12-20
KR101135173B1 (ko) 2012-04-16
US8809295B2 (en) 2014-08-19
KR20110085153A (ko) 2011-07-27

Similar Documents

Publication Publication Date Title
PH12020500203A1 (en) Identification of lkb1 mutation as a predictive boimarker for sensitivity to tor kinase inhibitors
PH12022551013A1 (en) Pyridazinones as parp7 inhibitors
EP4234551A3 (en) Pyridazinones as parp7 inhibitors
PH12018502355A1 (en) Enzyme inhibitors
MX342128B (es) Compuestos farmaceuticos.
PH12012502485A1 (en) Novel modified release dosage forms of xanthine oxidoreductase inhibitor or xanthine oxidase inhibitors
EA201200559A1 (ru) Способы назначения терапии пирфенидоном
WO2012016133A3 (en) Ros1 kinase inhibitors for the treatment of glioblastoma and other p53-deficient cancers
EA201291107A1 (ru) Соединения, ингибирующие металлоферменты
WO2009044173A3 (en) Methods of treating cancer using notch pathway inhibitors
NZ628054A (en) Treatment of addiction and impulse-control disorders using pde7 inhibitors
PH12013502370A1 (en) Multiheteroaryl compounds as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases
AU2011326186A8 (en) Selective glycosidase inhibitors and uses thereof
EA201590262A1 (ru) Комбинированное лечение меланомы, включающее введение кобиметиниба и вемурафениба
WO2012170776A3 (en) Methods of determining a patient's prognosis for recurrence of prostate cancer and/or determining a course of treatment for prostate cancer following a radical prostatectomy
MX2010005768A (es) Composiciones y métodos para inhibir la activación del arnbc-dependiente de la proteina de la kinasa y la inhibición del crecimiento tumoral.
WO2012021778A3 (en) Methods for blocking cell proliferation and treating diseases and conditions responsive to cell growth inhibition
WO2012037299A3 (en) Fatty acid synthase inhibitors
NZ596387A (en) Anti-obesity agent comprising compound containing benzotropolone ring
PH12022550130A1 (en) Enzyme inhibitors
WO2010101888A3 (en) Methods and compositions for treatment of tumor metastasis
AU2020258568A8 (en) CD73 inhibitors
WO2013037943A8 (en) Compositions and methods for treating cancer using pi3k beta inhibitor and mapk pathway inhibitor, including mek and raf inhibitors
WO2011090283A3 (ko) Ｓｈ３ｒｆ２ 발현 또는 활성 억제제를 함유하는 암의 예방 또는 치료용 조성물
WO2009058908A3 (en) Methods for prognosing the ability of a zearalenone analog compound to treat cancer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11734832

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 13574055

Country of ref document: US

122 Ep: pct application non-entry in european phase

Ref document number: 11734832

Country of ref document: EP

Kind code of ref document: A2